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Background: Tumor-derived exosomes have been viewed as a source of tumor antigens that can be used to
induce anti-tumor immune responses. In the current study, we aim to investigate the regulatory effect of the
epigenetic drug MS-275 on hepatoma G2 (HepG2) cell-derived exosomes, especially for their immunostimulatory
properties and alteration of some non-specific immune protein expression, such as heat shock protein (HSP) 70,
major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA) and MICB.
Methods: MS-275 was used to modulate the secretion of exosomes in human HepG2 cells, and exosomes from
untreated HepG2 cells served as negative controls. RT-PCR was used to test the expression of HSP70, MICA and
MICB in HepG2 cells. Immunogold labeling of exosomes and western blotting analysis were carried out to compare
the expression of HSP70, MICA and MICB proteins in exosomes with or without MS-275 treatment. A natural killer
(NK) cell cytotoxicity assay and peripheral blood mononuclear cell (PBMC) proliferation assay were used to evaluate
the effect of MS-275 on the immunostimulatory ability of exosomes.
Results: Immunogold labeling and western blot analysis showed that modification of MS-275 increased the
expression of HSP70 and MICB in exosomes. RT-PCR showed the mRNA levels of HSP70 and MICB were upregulated
in HepG2 cells and were consistent with their protein levels in exosomes. The exosomes modified by MS-275 could
significantly increase the cytotoxicity of NK cells and proliferation of PBMC (P < 0.05).
Conclusions: The non-specific immune response of exosomes derived from HepG2 cells could be enhanced with
treatment by the histone deacetylase inhibitor (HDACi) drug MS-275; this could provide a potential tumor vaccine
strategy against liver cancer.
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Exosomes are small membrane-bound particles with a
diameter of 30 to 100 nm; exosomes can be released from
both normal and diseased cells, such as neoplastic cells, to
the blood and other bodily fluids [1-3]. They contain signal
proteins and/or peptides, microRNAs, mRNAs, and lipids
[4,5], and, after release from diseased or normal cells, some
exosomes are transported to distant sites by blood [6,7].
Studies have shown that exosomes secreted by tumor cells
have immunosuppressive and pro-cancer activities [3,8];* Correspondence: wenhuaxiao77@163.com
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stated.both in vivo and in vitro evidence has showed that exo-
somes derived from tumor cells can augment an anti-
tumor response [9,10]. However, the capacity of tumor-
derived exosomes in the cellular immune response against
tumors is limited by numerous factors, including the hete-
rogeneity of tumor antigens, the type and molecular
chaperone of immune molecules in different tumor cells,
the insufficient expression of tumor-associated antigens
and immune molecules, the inhibited immune cell prolife-
ration by tumor-derived exosomes, and downregulated
NKG2D ligand expression at the tumor cell surface which
influences the activity of natural killer (NK) cells and their
cytotoxicity to tumor cells [11-13].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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(HDACi) drugs which is commonly used as an epigen-
etic drug to upregulate tumor specific antigens such as
human leukocyte antigen-I, human leukocyte antigen-II,
co-stimulatory molecule B7, and immune adhesion
molecules. MS-275 could enhance the specific and non-
specific anti-tumor immune reaction. In this study, we
attempted to explore the effects of MS-275 on the
release and function of exosome-related immune mole-
cules in hepatoma G2 (HepG2) cells.Methods
Preparation of peripheral blood mononuclear cells and
natural killer cells
Following approval from our hospital ethics committee,
20 ml peripheral blood samples were collected into a
50-ml CPT cell preparation tube (Becton Dickinson,
Cowley, UK) from healthy donors who signed consent
forms. Peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll gradient centrifugation as previously de-
scribed [14]. After washing in PBS, cells were resuspended
in RPMI 1640 medium at a concentration of 1 × 107/ml.
Peripheral blood NK cells were negatively selected
from PBMCs by magnetic sorting using the Mini MACS
NK isolation kit (Miltenyi Biotech, Shanghai, China).
Isolated NK cells were activated by phytohemagglutinin
(PHA;10 ng/ml; Sigma-Aldrich, St Louis, MO, USA) and
IL-2 (1,000 IU/ml) in RPMI 1640 medium supplemented
with 10% FCS.Isolation of exosomes from culture supernatants with
or without MS-275
The human HepG2 cell line (JCRB1054) was obtained from
Beijing Cancer Research and Prevention Institute, Beijing,
China. Cells were cultured in DMEM supplemented with
10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin
at 37°C in an atmosphere of 5% CO2. MS-275 was pur-
chased from Sigma-Aldrich.
Log phased HepG2 cells were plated into dishes at a
density of 3 × 104/ml. After 24-hour culture, MS-275
(1 × 10-6 mol/l) was added. PBMCs treated with PHA
served as the blank control. After incubation for 72
hours, culture media was collected and sequentially cen-
trifuged at 300 × g at 4°C for 3 minutes, floating cells
were removed, and then centrifuged at 2,000 × g for 15
minutes at 4°C and at 12,000 × g at 4°C for 35 minutes.
Cell debris was then removed. Supernatants were col-
lected and passed through a 0.22 μm filter. Exosomes
were isolated by ultra-centrifugation at 120,000 × g at
4°C for 2 hours, and quantified by measuring their pro-
tein concentration with a BCA assay (μg/ml).
Exosomes pellets were stored at −80°C until use.Electron microscopic characterization and immunogold
labeling of exosomes
A total of 20 to 30 μl prepared exosomes were loaded
onto a copper net. Following air drying, 30 μl phospho-
tungstic acid solution (pH 6.8, 20 ml/l) was added and a
negative staining was performed at room temperature
for 1 minute. After drying at room temperature about 10
minutes, staining signals of the microcapsule membrane
structure (30 to 80 nm) were observed under a photo-
graphic transmission electron microscope.
For immunogold labeling, exosomes were applied to
formvar carbon-coated copper grids and incubated with
rabbit anti-human heat shock protein (HSP)70 monoclo-
nal antibody (1:50 diluted, StressGen Biotechnologies
Corporation, British Columbia, Canada), rabbit anti-
human anti-major histocompatibility complex (MHC)
class I polypeptide-related sequence A (MICA) antibody
and rabbit anti-human anti-MICB monoclonal antibody
(1:100 diluted, Biolegend, Sandiego, CA, USA), respect-
ively, at room temperature for 1 hour. Incubation with
PBS served as a blank control. Following washing in
PBS, exosomes were incubated with 20 μl protein A
immunogold (SPA) (1:15 diluted) at room temperature
for 30 minutes. A negative dye containing 15 μl uranyl
acetate was performed at room temperature for 30 sec-
onds. Positively labeled exosomes were seen as vesicles
containing black colloidal gold particles under the trans-
mission electron microscope. The numbers of exosomes
were counted in 10 random fields (1000 nm × 700 nm).
Counting was repeated five times and the average was
calculated for each of the specimens.3H-TdR incorporation assay of peripheral blood
mononuclear cell proliferation
PBMCs were plated into a 96-well plate at a concentra-
tion of 5,000 cells/well in RPMI 1640 medium supple-
mented with 10% FBS; streptomycin and penicillin were
added at a final concentration of 50 μg/l with or without
PHA (100 μl loaded). In total, three groups were
involved. The wells without exosomes served as controls,
and the other two groups had either normal exosomes
added or exosomes modified with MS-275, respectively
(final exosome concentration 10 μg/ml). After culture
at 37°C in an atmosphere of 5% CO2 overnight,
H3-TdR was added to each well at a concentration of
3.7 × 104 Bq. Following an incubation for 6 hours,
1 mol/l NaOH was used to break the cell membrane.
Scintillation fluid and the quenching agent were
added, and the H3-TdR incorporation was quantified
as counts per minute (CPM) on a beta liquid scintil-
lation counter (PerkinElmer Life Sciences, Waltham,
MA, USA).
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After incubation with MS-275 for 3 days, HepG2 cells
were washed and prepared for analysis. Total RNA was
isolated using the RNeasy Micro Kit (Qiagen, Hilden,
Germany). Single-strand cDNA was synthesized and
HSP70, MICA and MICB were amplified using the fol-
lowing specific primers (Eurofins MWG Operon,
Ebersberg, Germany): HSP70 forward 5′-TGTGG
CTTCCTTCGTTATTGG-3′ and reverse 5′-GCCAG
CATCATTCACCACCAT-3′; MICA sense, 5′-CAGGG
ACTTGACAGGGAAC-3′ and antisense, 5′-CCTCTCC
TCGGCAAATCCT-3′; MICB sense, 5′-ACCGAGGAC
TTGACAGAGA-3′ and antisense, 5′-CCGCTGATG
TTTTC CTTCT-3′; and reverse: 5′-CACCTTGCCGT
GTTGGAA-3′ GAPDH forward: 5′-CCACTCCTCCAC
CTTTGAC-3′ and reverse: 5′-ACCCTGTTGCTG
TAGCCA-3′. The PCR products were separated on 2%
agarose gel and visualized with ethidium bromide.
GADPH served as a control.
Western blotting analysis
Protein electrophoresis was performed as previously de-
scribed [15]. After transfer, membrane blots were stained
with Ponceau S to verify quality of transfer and equal load-
ing. Blots were probed for HSP70 and MICA and MICB
using primary anti-HSP70 (1:500, StressGen) and MICA
and MICB (Santa Cruz Biotechnology, Santa Cruz, CA)
antibodies, respectively; horseradish peroxidase-conjuga-
ted anti-goat served as a secondary antibody (Amersham/
GE, Piscataway, NJ, USA). Specific immunoreactive signals
were developed with a chemiluminescent agent (Pierce,
Rockford, IL, USA). Densitometric analysis was performed
as previously described [16].
Cytotoxicity assay
An AlamarBlue based one-step fluorimetric assay was per-
formed as previously described [17]. Briefly, prepared nor-
mal exsomes and MS-275 modified exosomes (10 μg/ml)
were added to the target HepG2 cells in 96-well flat-
bottomed plates, and effector cells (NK cells) were added;
mixed effector and target cells were at ratios of 1:5, 1:10,
1:20, and 1:40, respectively. The mixtures were incubated
with AlamarBlue in a humidified environment with 5%
CO2 at 37°C overnight. The fluorescent signals of the Ala-
marBlue were read by a Synergy HT plate reader (Biotek,
Winooski, VT, USA) at excitation of 530 nm and emission
of 590 nm, respectively. The cytotoxicity of NK cell was
calculated using the following formula:NK cell cytotoxicity %ð Þ ¼ AF of observation group–AFð
AF of fully lysis target cells–ðwhere AF is the average fluorescence units.Statistical analysis
Data were analyzed by chi-square test using SPSS 19.0
software IBM, Chicago, IL, USA. Differences were con-
sidered significant at P < 0.05.Results and discussion
Electron microscopic characteristics of exosomes
The exosomes secreted from HepG2 cells were round or
oval membrane microcapsules with a diameter of 30 to
80 nm when observed under an electron microscope;
the composition within the membrane showed a low
electronic density (Figure 1A). We counted the average
exosome number treated with or without MS-275, and
the exosomes secreted by HepG2 cells increased greatly
(P < 0.05) after treatment with MS-275 (Figure 1B). The
immunogold labeling showed black granular colloidal
gold signals existed in the capsular membrane and cav-
ity. Compared with untreated HepG2 cells, MS-275-
treated HepG2 cells expressed significantly higher (P <
0.001) levels of HSP70 and MICB-positive colloidal gold
particles in exosomes (Figure 2); although we observed
relative high levels of MICA after treatment with MS-
275, there was no difference when compared with un-
treated exosomes. In untreated cells, the number of
HSP70-positive colloidal gold particles was much higher
than MICA- and MICB-positive particles.Effect of MS-275 on peripheral blood mononuclear cell
proliferation
The CPM value decreased in the exosomes modified by
drug group (19,411 ± 786.63) when compared with the
value in the blank control group (23,974 ± 2,024.31), but
the difference between these two groups failed to reach a
significant level (P > 0.05). In contrast, the CPM value was
decreased significantly in the group of exosomes without
drug modification (3,863 ± 20.88) when compared with
the value in the blank control group (P < 0.001) and the
exosomes modified by drug group (P < 0.05).MS-275 induced elevated expression of heat shock
protein 70, MICA, and MICB in hepatoma G2 cells
After treatment with MS-275, the mRNA expression of
HSP70, MICA, and MICB were all upregulated in
HepG2 cells, compared to cells without treatment by
MS-275. The relative expression of HSP70, MICA, andof target cells–AF of effector cellsÞ=
AF of target cellsÞ  100%
Figure 1 The electron microscope observation result of exosomes secreted from hepatoma G2 cells. (A) The microcapsule of exosomes
have a diameter of 30 to 80 nm. (B) Column comparison of exosome expression with or without MS-275.
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spectively (Figure 3).
Western blotting analysis results
Consistent with mRNA expression, western blotting
analysis showed the specific protein bands of HSP70Figure 2 The comparison of immunogold labeling of hepatoma G2 ce
heat shock protein (HSP)70, MICA, and MICB molecular colloidal gold partic
(P < 0.01). (A) HSP70 protein without drug. (B) HSP70 protein treated with
drug. (E) MICB protein without drug. (F) MICB protein treated with drug.(147 kDa), MICA (73 kDa) and MICB (47 kDa) in
the HepG2 cell-derived exosomes (Figure 4). MS-
275 modification significantly increased MICB and
HSP70 protein in the exosomes of HepG2 cells
compared to those without MS-275 treatment
(P < 0.05).lls treated with or without MS-275. After treatment with MS-275,
les increased in exosomes with statistical significance
drug. (C) MICA protein without drug. (D) MICA protein treated with
Figure 3 The mRNA expression of heat shock protein (HSP)70,
MICA and MICB in hepatoma G2 cells.
Table 1 Percentage of hepatoma G2 cells killed by
natural killer cells at various effector: target cell ratios
with or without MS-275 modification
Effector cell (NK cells): target cell ratios
5:1 10:1 20:1 40:1
EWD group (%) 1. 69 ± 0.13 2. 47 ± 0. 84 5. 21 ±1. 07 5. 77 ± 0. 83
EMD group (%) 25. 32 ± 1. 31* 42. 27 ± 1.67* 57. 53 ± 2.13* 70.21 ± 3. 01*
*P < 0.05 compared with EWD group. EMD: exosomes with drug modification;
EWD, exosomes without drug modification; NK, natural killer.
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We evaluated the cytotoxicity of NK cells against HepG2
cells at various NK/HepG2 cell ratios with normal or
MS-275 modified exosomes. The results are presented
in Table 1. As the NK/HepG2 cell ratio increased, the
dead HepG2 cells increased. MS-275 significantlyFigure 4 Comparison expression of heat shock protein (HSP)70,
MICA and MICB protein with or without MS-275. (A) Western
blot showing the protein band of HSP70, MICA and MICB at the
molecular weights of 147, 73 and 47 kDa, respectively. EMD,
exosomes with drug modification; EWD, exosomes without drug
modification. (B) Histogram comparison; after treatment with
MS-275, the expression of MICA, MICB and HSP70 in HepG2 cell
exosomes (EMD) increased significantly compared with untreated
cells (EWD).increased the cytotoxicity of NK cells at the same
effector/target cell ratio (P < 0.05).
Exosomes are vesicles formed by ‘inward/reverse bud-
ding’ of the limiting membrane of the multivesicular
bodies in the late endocytic compartment that are re-
leased upon the fusion of multivesicular bodies with the
plasma membrane [18,19]. Exosome proteins derived
from the tumor cell membrane are rich in tumor antigen
chaperone molecules such as HSP70, 80, 90 and MHC
class I molecules. HSP70 originated from tumor exo-
somes can selectively activate NK cell activity, thus lead-
ing to the migration and proliferation of tumor cell and
augmentation of an immune response [20]. Due to their
molecular chaperone properties, HSPs can bind tumor-
specific peptides and deliver them deep into the antigen-
processing pathways of antigen-presenting cells. In this
way, HSP-based vaccines can activate tumor-specific
immunity, trigger the proliferation and cytotoxic T
lymphocyte capabilities of cancer-specific CD8+ T cells,
and inhibit tumor growth [21]. However, the immune
stimulatory activity of exosomes in tumor cells is
dependent on their expression level. Moreover, tumor-
derived exosomes lack antigen presentation stimulators
such as T-cell-activating protein, latent membrane pro-
tein and Tapasin; as a result, their tumor immunosup-
pressive activity is substantially compromised [22].
The extent of exosome secretion in different cell types
can be modulated by either ligand cognition or stresses.
For example, radiation treatment is able to increase the
level of exosomes secreted by tumor cells, a process pos-
sibly involving the activation of p53 and the subsequent
upregulation of the trans-membrane protein tumor
suppressor-activated pathway 6 [23,24]. HDACi exert
their effects predominantly by altering histone acetyl-
ation, which is normally controlled by a balance between
histone deacetylases and histone acetyltransferases [25].
Increased histone acetylation induced by HDACi results
in activation of the genes responsible for: 1) generating an
intracellular pro-apoptotic milieu [26], 2) increasing sur-
face expression of TNF, super-family death receptors like
Fas, TNF-related apoptosis-inducing receptor and TNF-
receptors [27], 3) increasing the expression of MHC mole-
cules and other molecules involved in antigen processing
and presentation [22,28], and 4) increasing expression of
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and ligands for NK activating receptors [29].
In our study, we found MS-275 was able to increase
the secretion of MICB and HSP70 in exosomes secreted
by HepG2 cells significantly. We also observed that MS-
275 modification could attenuate the inhibitory effect of
naive exosomes on the cytotoxicity of NK cells, possibly
through upregulating the expression of the MICA,
MICB, and HSP70 on the tumor cell surface. These ob-
servations were consistent with the results of electron
microscopic assessment.
Conclusion
In conclusion, soluble immunoregulatory molecules in
the exosomes secreted by HepG2 cells have a significant
inhibitory effect on lymphocyte proliferation. MS-275
modified exosomes enhance the cytotoxic effect of NK
cells significantly through upregulating the expression of
MICA, MICB and HSP70. Our observations suggest that
HDACi-modified tumor cell-derived exosomes may
function as potential tumor vaccines against liver cancer.
We only observed one HDACi drug (MS-275) and one
tumor cell line (HepG2); therefore, it is difficult to con-
clude that this conclusion is universally represented. An
in-depth study is therefore needed, but our study can
provide some reference for similar research.
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